ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 464

Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis

Yutaro Yamada1, Kentaro Inui2, Tadashi Okano3, Yuko Sugioka1, Kenji Mamoto4, Kazuki Orita5, Tatsuya Koike6, Masahiro Tada7 and Hiroaki Nakamura3, 1Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Orhopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 5Orthopedics, Shirahama hamayu Hospital, Shirahama, Japan, 6Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, 7Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Joint destruction and matrix metalloproteinase (MMP)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Serum level of MMP-3 rises by synovial inflammation in patients with rheumatoid arthritis (RA). It destroys articular cartilage such as proteoglycans so that it has been used as a clinical biomarker of joint destruction. Also it has been reported as a predictor for radiographic progression. The purposes of this study are to confirm a relation between baseline MMP-3 and radiographic progression at 1 year and to examine the association of the MMP-3 level with ultrasonography (US) findings.

Methods: A total of 259 (213 women) consecutive patients with RA were enrolled in this study. Their baseline data including age, sex, disease duration, use of glucocorticoid (GC) or DMARDs, disease activity (DAS28), laboratory data (MMP-3, CRP, RF and ACPA),  radiographic assessment (modified total Sharp score; mTSS) and the power doppler score (PD) in US assessment at digits and wrists were collected. Baseline MMP-3 level was analyzed in association with the baseline PD value and changes in mTSS (ƒ¢mTSS), erosion score (ƒ¢ERN), joint space narrowing (ƒ¢JSN) at 1 year from baseline using Pearsonfs correlation method. Correlations between ƒ¢MMP-3 and ƒ¢mTSS, or ƒ¢PD were also analyzed. Multiple regression analysis was performed with ƒ¢mTSS as the outcome for baseline variables. Statistical analysis was performed separately by sex because the upper normal limits of MMP-3 is different between male and female.

Results: There was no correlation between baseline MMP-3 and disease duration, GC use, DAS28, RF, CRP and mTSS. There was moderate correlations between baseline MMP-3, ĢMMP-3, ĢmTSS and ĢJSN at 1 year only in men. There was also a weak correlation between the baseline MMP-3 and baseline PD score only in men. However, MMP-3 could not predict joint destruction at 1 year in women. Multiple regression analysis revealed that the baseline MMP-3 level correlated independently with the ĢmTSS only in men (p= 0.0031), whereas the baseline PD score was correlated independently with the ĢmTSS in women (p= 0.0003).

Conclusion: The baseline MMP-3 level was a good predictor for deterioration of the mTSS at 1 year in male patients with RA, but not in female patients. On the other hand, the baseline PD score was a useful predictor of joint destruction in female patients with RA.

variables

correlation coefficient

confidence interval

p

Male patients

Baseline MMP-3

ĢmTSS

0.501a

[0.246, 0.691]

<0.001

ĢERN

0.336b

[0.051, 0.571]

0.022

ĢJSN

0.542a

[0.299, 0.719]

<0.0001

baseline-PD

0.228b

[-0.074, 0.492]

0.136

ĢMMP-3

ĢmTSS

-0.435a

[-0.644, -0.165]

0.003

ĢERN

-0.325b

[-0.562, -0.038]

0.028

ĢJSN

-0.436a

[-0.645, -0.167]

0.002

ĢPD

0.134

[-0.170, 0.414]

0.387

Female patients

Baseline MMP-3

ĢmTSS

0.0011

[-0.130, 0.132]

0.987

ĢERN

0.0188

[-0.113, 0.150]

0.780

ĢJSN

-0.0148

[-0.146, 0.117]

0.826

baseline-PD

0.0985

[-0.040, 0.233]

0.163

ĢMMP-3

ĢmTSS

-0.0344

[-0.165, 0.098]

0.610

ĢERN

-0.0485

[-0.179, 0.083]

0.472

ĢJSN

-0.0127

[-0.144, 0.119]

0.851

ĢPD

0.134

[-0.0058, 0.270]

0.060

Ģ: difference in values from baseline to 1 year; MMP-3: matrix metalloproteinase; mTSS: modified total Sharp score; ERN: erosion score; JSN: joint space narrowing; PD: power Doppler.

a: Moderate correlation, b: Weak correlation., Statistical analysis was performed using Pearsonfs correlation.


Disclosure: Y. Yamada, None; K. Inui, None; T. Okano, None; Y. Sugioka, None; K. Mamoto, None; K. Orita, None; T. Koike, None; M. Tada, None; H. Nakamura, None.

To cite this abstract in AMA style:

Yamada Y, Inui K, Okano T, Sugioka Y, Mamoto K, Orita K, Koike T, Tada M, Nakamura H. Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/value-of-matrix-metalloproteinase-3-regarding-prediction-for-joint-destruction-at-1-year-is-different-between-sexes-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-matrix-metalloproteinase-3-regarding-prediction-for-joint-destruction-at-1-year-is-different-between-sexes-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology